First line of biological drugs in rheumatoid arthritis: a medication persistence analysis

References

• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001 Sep 15;358(9285):903–911.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chronic diseases and health promotion. Chronic rheumatic conditions; 2018 [cited 2018 Jul 5]. Available from: www.who.int/chp/topics/rheumatic/en/
   Google Scholar
• Brasil. Ministério da Saúde. Portaria conjunta nº 15, de 11 de dezembro de 2017. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatoide. Brasil; 2017 [cited 2018 Jul 5]. Available from: www.portalarquivos2.saude.gov.br/images/pdf/2018/janeiro/04/Portaria-Conjunta-15-PCDT-da-AR-11-12-2017.pdf
   Google Scholar
• Elkin E, Bergman MJ, Kamath T, et al. Reasons for discontinuation of biologic agents in rheumatoid arthritis patients. ACR/ARHP 2013 Annual Meeting. Abstract no. 1468.
   Google Scholar
• Strand V, Miller P, Williams SA, et al. Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the corrona RA registry. Rheumatol Ther. 2017 August 22;4:489–502.
   Web of Science ®Google Scholar
• Titton DC, Silveira IG, Louzada-Junior P, et al. Brazilian biologic registry: biobadaBrasil implementation process and preliminary results. Rev Bras Reumatol. 2011;51(2):152–160.
   PubMedGoogle Scholar
• Neovius M, Arkema EV, Olsson H, et al. ARTIS study group. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015 Feb;74(2):354–360.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015 Nov;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• Guerra Junior AA, Pereira RG, Andrade EIG, et al. Building the national database of health centred on the individual: administrative and epidemiological record linkage - Brazil, 2000–2015. Int J Popul Data Sci. 2018;3: 3:20. DOI:10.23889/ijpds.v3i1.446
   Google Scholar
• Böckerman P, Johansson E, Helakorpi S, et al. Economic inequality andpopulation health: looking beyond aggregate indicators. Sociol Health Illn. 2009 Apr;31(3):422–440.
   PubMed Web of Science ®Google Scholar
• Jutz R. The role of income inequality and social policies on income-relatedhealth inequalities in Europe. Int J Equity Health. 2015 Oct 31;14:117.
   PubMed Web of Science ®Google Scholar
• Acurcio FA, Machado MA, Moura CS, et al. Medication persistence of disease-modifying antirheumatic drugs and anti-tumor necrosis factor agents in a cohort of patients with rheumatoid arthritis in Brazil. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1489–1496.
   PubMed Web of Science ®Google Scholar
• Chastek B, White J, Van Voorhis D, et al. A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv Ther. 2016 Apr;33(4):626–642.
   PubMed Web of Science ®Google Scholar
• Howe A, Eyck LT, Dufour R, et al. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm. 2014 Dec;20(12):1236–1244.
   PubMed Web of Science ®Google Scholar
• Johnston SS, McMorrow D, Farr AM, et al. Comparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologic. Rheumatol Ther. 2015 Jun;2(1):59–71.
   PubMed Web of Science ®Google Scholar
• Cho SK, Sung YK, Choi CB, et al. Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int. 2012 Dec;32(12):3851–3856.
   PubMed Web of Science ®Google Scholar
• Sangiorgi D, Benucci M, Nappi C, et al. Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics. 2015;9:119–127.
   PubMedGoogle Scholar
• Neubauer S, Cifaldi M, Mittendorf T, et al. Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Econ Rev. 2014;4:32.
   PubMedGoogle Scholar
• Esposti LD, Favalli EG, Sangiorgi D, et al. Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. Clinicoecon Outcomes Res. 2017;9:9–17.
   PubMed Web of Science ®Google Scholar
• Kaufmann J, Feist E, Roske AE, et al. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol. 2013 Sep;32(9):1347–1355.
   PubMed Web of Science ®Google Scholar
• Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis. BioDrugs. 2015 Aug;29(4):241–258.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Choy E, Kivitz A, et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Jun;76(6):1078–1085.
   PubMed Web of Science ®Google Scholar
• Sigaux J, Hamze M, Daien C, et al. Immunogenicity of tocilizumab in patients withrheumatoid arthritis. Joint Bone Spine. 2017 Jan;84(1):39–45.
   PubMed Web of Science ®Google Scholar
• Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate inpatients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013 May;65(5):718–728.
   PubMed Web of Science ®Google Scholar
• Martín-López M, Carmona L, Balsa A, et al. Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. Rheumatol Int. 2018 Jun;38(6):975–983.
   PubMed Web of Science ®Google Scholar
• Garcês S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014 Jun;73(6):1138–1143.
   PubMed Web of Science ®Google Scholar
• Fidder HH, Singendonk MM, van der Have M, et al. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013 Jul 21;19(27):4344–4350.
   PubMed Web of Science ®Google Scholar
• Bhoi P, Bessette L, Bell MJ, et al. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open. 2017 Sep 18;7(9):e015872.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Ellis L, Bolge SC, et al. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther. 2014 May;36(5):737–747.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012 Sep;18(7):527–539.
   PubMed Web of Science ®Google Scholar
• Malaviya AP, Ostör AJ. Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept. Patient Prefer Adherence. 2012;6:589–596.
   PubMed Web of Science ®Google Scholar
• Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014 Dec;127(12):1208–1232.
   PubMed Web of Science ®Google Scholar
• Tank ND, Karelia BN, Vegada BN. Biological response modifiers in rheumatoid arthritis: systematic review and meta-analysis of safety. J Pharmacol Pharmacother. 2017 July–Sep;8(3):92–105.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Sruamsiri R. Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents. Curr Med Res Opin. 2017 Jan;33(1):101–107.
   PubMed Web of Science ®Google Scholar
• Travassos C, Oliveira EX, Viacava F. Geographic and social inequalities in the access to health services in Brazil: 1998 and 2003. Cien Saude Colet. 2006;11:975–986.
   Google Scholar
• Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Relatório de Recomendação da Comissão Nacional de Incorporação de Tecnologias no SUS – CONITEC - 12. Medicamentos Biológicos (infliximabe, etanercepte, adalimumabe, rituximabe, abatacepte, tocilizumabe, golimumabe e certolizumabe pegol) para o tratamento da Artrite Reumatoide. Julho de; 2012 [cited 2018 Jul 5]. Available from: www.conitec.gov.br/images/Incorporados/Biologicos-ArtriteReumatoide-final.pdf
   Google Scholar
• Turkstra E, Ng SK, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin. 2011 Oct; 27(10):1885–1897.
   PubMed Web of Science ®Google Scholar
• Choi M, Hyun MK, Choi S, et al. Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison. Korean J Intern Med. 2017 May;32(3):536–547.
   PubMed Web of Science ®Google Scholar
• Brasil. Ministério da Saúde. Ministério da Saúde lança conjunto de ações para melhoria da assistência farmacêutica [cited 2018 Jul 5]. Available from: www.portalarquivos2.saude.gov.br/images/pdf/2018/janeiro/24/Evento-Assistencia-Farmaceutica.pdf
   Google Scholar
• Brasil. Ministério da Saúde. Departamento de Assistência Farmacêutica. NOTA TÉCNICA Nº 41/2018-DAF/SCTIE/MS. Brasil; 2018 [cited 2018 Jul 5]. Available from: www.saude.rs.gov.br/upload/arquivos/carga20180431/25143142-nota-tecnica-ar-n41-2018-daf.pdf
   Google Scholar